Humanigen says lenzilumab demonstrated 80% reduction in relative risk of invasive mechanical ventilation and/or death in coronavirus patients
Humanigen Inc (OTCMKTS:HGEN) has said the first case-control data of lenzilumab in severe coronavirus (COVID-19) cases demonstrated an 80% reduction in relative risk of invasive mechanical ventilation (IMV) and/or death for patients treated with the drug compared to a matched control group.
Lenzilumab, an anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody drug candidate, is being evaluated in an ongoing Phase III trial and was selected by the National Institutes of Health for its COVID-19 Big Effect Trial.
Humanigen said the manuscript of the study titled “GM-CSF neutralization with lenzilumab in severe COVID-19 patients: A case-control study” was published in Mayo Clinic Proceedings, a premier peer-reviewed journal.
READ: Humanigen taps drug development expert Edward Jordan for chief commercial officer role ahead of lenzilumab launch
“We believe these to be some of the most compelling data published to date of an investigational therapeutic with potential to substantially fight the COVID-19 pandemic and we look forward to validating these data with the results of our ongoing Phase III study,” Dr Dale Chappell, chief scientific officer of Humanigen said in a statement.
“We also appreciate that the stakes are even higher after some other pathways being explored across the industry haven’t met their clinical endpoints and rates of infection are increasing in many areas.”
The study involved a total of 39 patients, including 12 treated with lenzilumab, and 27 contemporaneous matched control patients who received standard of care treatment.
The company said the lenzilumab treatment was associated with a reduction in risk of progression to IMV and/or death compared to matched controls (8% vs 41%). Median time to resolution of acute respiratory distress syndrome (ARDS) was one day in the lenzilumab treatment arm versus eight days in the control group. Patients treated with lenzilumab were discharged in a median of five days versus 11 days in the control arm.
READ: Humanigen gets regulatory nod to begin Phase 3 coronavirus trial of lenzilumab in Brazil
Lenzilumab treatment was also associated with a significant reduction in the inflammatory marker c-reactive protein (CRP) relative to the control group and an improvement in lymphocyte counts relative to the control group.
California-based Humanigen said the data suggest that GM-CSF neutralization with lenzilumab may restore balance to the dysregulated immune response induced by SARS-CoV-2 by supressing the myeloid inflammatory response and improving T-cell counts that are thought to be responsible for viral clearance.
“Based on the pathophysiology of an immune hyper-response or cytokine storm following SARS-CoV-2 infection, these data along with prior studies conducted at Mayo Clinic on GM-CSF depletion point to the potential impact of treating cytokine storm in COVID-19 with lenzilumab,” said Humanigen CEO Dr Cameron Durrant.
“As vaccine development continues to progress and we await compelling data, we must also look toward nearer-term achievable goals, such as bringing effective treatments to hospitalized COVID-19 patients this winter. Having a therapeutic that can reduce the risk of ventilation and death from COVID-19 would have a dramatic impact on the arc of the current pandemic both nationally and globally, and potentially help re-set societal response to the pandemic.”
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham
Story by ProactiveInvestors
Source: https://www.proactiveinvestors.com/companies/news/927997/humanigen-says-lenzilumab-demonstrated-80-reduction-in-relative-risk-of-invasive-mechanical-ventilation-andor-death-in-coronavirus-patients-927997.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
LION'S MANE PRODUCT
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.
